MACLEODS PHARMA supplier risk profile Q1-2026: India sourcing, pharmaceutical imports, risk score 78/B.
MACLEODS PHARMA imported 65 shipments in Q1 2026 across three HS codes, sourced entirely from a single supplier in India. The importer relies on MACLEODS PHARMACEUTICALS for 100% of its volume. Pharmaceutical products classified under HS 300490 dominate the portfolio, accounting for 75.4% of shipments, with smaller volumes of HS 300432 and HS 300420 products.
Trigram screen against OFAC SDN, BIS Entity List, UFLPA Entity List, SAM Exclusions, EU FSF, UK HMT, UN SC, and 25+ allied jurisdictions.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
The importer registered zero sanctions watchlist matches in Q1 2026. No suppliers in the sourcing network show exposure to forced-labor risks under UFLPA designations.
1 distinct tier-1 suppliers in Q1 2026
| MACLEODS PHARMACEUTICALS | India | 65 |
Share of Q1 2026 inbound shipments by source country
1 tier-2 + 0 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.